Fatal Anti-Ma2 Encephalitis Related to Treatment of Malignant Pleural Mesothelioma With a Combination of Anti-Programmed Death 1 and Anti-Cytotoxic T-Lymphocyte Associated Protein 4 Antibodies
Du Rusquec, P.; Peyre, A.; Toulgoat, F.; Honnorat, J.; Raimbourg, J.
Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer 14(8): E174-E176
2019
ISSN/ISBN: 1556-0864 PMID: 31345342 DOI: 10.1016/j.jtho.2019.03.017
Accession: 069183392
PDF emailed within 0-6 h: $19.90
Related References
DuRusquec, P.; Peyre, A.; Toulgoat, F.; Honnorat, J.; Raimbourg, J. 2019: Fatal Anti-Ma2 Encephalitis Related to Treatment of Malignant Pleural Mesothelioma With aCombination of Anti-Programmed Death 1 and Anti Cytotoxic T-Lymphocyte Associated Protein 4 Antibodies Journal of Thoracic Oncology 14(8): e174-e176Hwang, S.Ji.Eun.; Park, J.Jae.Won.; Wakade, D.; Chou, S.; Byth, K.; Fernandez-Penas, P. 2019: Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma Melanoma Research 29(2): 172-177
Li, Q; Wang, W; Machino, Y; Yamada, T; Kita, K; Oshima, M; Sekido, Y; Tsuchiya, M; Suzuki, Y; Nan-ya, K-ichiro; Iida, S; Nakamura, K; Iwakiri, S; Itoi, K; Yano, S 2015: Therapeutic activity of glycoengineered anti-GM2 antibodies to malignant mesothelioma. GM2 expression in a clinical malignant pleural mesothelioma specimen determined by anti-GM2 antibody BIW-8962 Cancer Science 106(1): January Cover-January Cover
Bernard-Tessier, A.; Baldini, C.; Martin, P.; Champiat, Séphane.; Hollebecque, A.; Postel-Vinay, S.; Varga, A.; Bahleda, R.; Gazzah, A.; Michot, J-Marie.; Ribrag, V.; Armand, J-Pierre.; Marabelle, Aélien.; Soria, J-Charles.; Massard, C. 2018: Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression European Journal of Cancer 101: 160-164
Noguchi, M.; Nakajima, T.; Hirohashi, S.; Akiba, T.; Shimosato, Y. 1989: Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies Human Pathology 20(1): 53-57
Levite, M. 2014: Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. these autoimmune anti-glutamate receptor antibodies Journal of Neural Transmission 121(8): 1029-1075
Shaw, S.; Goldstein, G.; Springer, T.A.; Biddison, W.E. 1985: Susceptibility of cytotoxic T lymphocyte [CTL] clones to inhibition by anti-T3 and anti-T4 [but not anti-LFA-1] monoclonal antibodies varies with the avidity of CTL-target interaction The Journal of Immunology (1950) 134(5): 3019-3026
Shaw, S.; Goldstein, G.; Springer, T.A.; Biddison, W.E. 1985: Susceptibility of cytotoxic T lymphocyte (CTL) clones to inhibition by anti-T3 and anti-T4 (but not anti-LFA-1) monoclonal antibodies varies with the "avidity" of CTL-target interaction Journal of Immunology 134(5): 3019-3026
Hroncová, D; Binda, M; Šarga, P; Kičák, Fšek 1985: Susceptibility of cytotoxic lymphocyte (CTL) clones to inhibition by anti-T3 and anti-T4 (but not anti-LFA-1) monoclonal antibodies varies with the avidity of CTL-target interaction Human Immunology 12(2): 114-115
Abelson, N.M.; Rawson, A.J. 1961: Studies of blood group antibodies, V. Fractionation of examples of anti-B, anti-A,B, anti-P, anti-Jka, anti-Lea, anti-D, anti-CD, anti-K, anti-Fya, anti-s and anti-Good Transfusion 1: 116-123
Abelson, N.M.; Rawson, A.J. 1961: Studies of blood group antibodies. V. Fractionation of examples of anti-A,B, anti-M, anti-P, anti-Jka, anti-Lea, anti-D, anti-CD, anti-K, anti-Fya, anti-s and anti-Good Transfusion 1(2): 116-123
Sakai, G.; Saito, D.; Nakajima, R.; Hatano, M.; Noguchi, Y.; Kurihara, S.; Katayama, S.; Inoue, I.; Noda, M.; Shimada, A. 2018: Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes Journal of Diabetes Investigation 9(2): 448-449
Amini-Adle, M.; Piperno, M.; Tordo, Jérémie.; Thomas, L.; Dalle, Séphane.; Dubois, Vérie.; Marabelle, Aélien. 2018: Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti-CTLA-4 and Anti-Programmed Death 1 Combination Treatment Arthritis and Rheumatology 70(8): 1358
Mitchell, E.L.; Lau, P.Kar.Han.; Khoo, C.; Liew, D.; Leung, J.; Liu, B.; Rischin, A.; Frauman, A.G.; Kee, D.; Smith, K.; Brady, B.; Rischin, D.; Gibson, A.; Mileshkin, L.; Klein, O.; Weickhardt, A.; Arulananda, S.; Shackleton, M.; McArthur, G.; Östör, A.; Cebon, J.; Solomon, B.; Buchanan, R.Rc.; Wicks, I.P.; Lo, S.; Hicks, R.J.; Sandhu, S. 2018: Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series European Journal of Cancer 105: 88-102
Hamid, O.; Carvajal, R.D. 2013: Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy Expert Opinion on Biological Therapy 13(6): 847-861
Havran, W.L.; Fitch, F.W. 1988: Effects of anti-Lyt-2 and anti-L3T4 monoclonal antibodies on the function of cytotoxic T lymphocyte/helper T lymphocyte hybrid T cell clones Journal of Immunology 141(6): 1808-1812
Hashimoto, R.; Tanabe, E.; Otsuka, Y.; Yoneda, Y.; Kageyama, Y. 2021: Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma Case Reports in Neurology 13(3): 724-728
Hsu, P-Chih.; Li, S-Hong.; Yang, C-Ta. 2018: Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 13(11): e227-e230
Li, Q.; Wang, W.; Machino, Y.; Yamada, T.; Kita, K.; Oshima, M.; Sekido, Y.; Tsuchiya, M.; Suzuki, Y.; Nan-Ya, K.-i.; Iida, S.; Nakamura, K.; Iwakiri, S.; Itoi, K.; Yano, S. 2015: Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma Cancer Science 106(1): 102-107
Le Burel, Sébastien.; Champiat, Séphane.; Mateus, C.; Marabelle, Aélien.; Michot, J-Marie.; Robert, C.; Belkhir, R.; Soria, J-Charles.; Laghouati, S.; Voisin, A-Laure.; Fain, O.; Mékinian, Aène.; Coutte, L.; Szwebel, T-Anne.; Dunogeant, L.; Lioger, B.; Luxembourger, Cécile.; Mariette, X.; Lambotte, O. 2017: Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis European Journal of Cancer 82: 34-44